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Schedule-Dependent Interaction between the Proteosome
Inhibitor Bortezomib and the EGFR-TK Inhibitor Erlotinib in
Human Non-small Cell Lung Cancer Cell Lines
Bilal Piperdi, MD,* Yi-He Ling, PhD,† and Roman Perez-Soler, MD†
Introduction: Both erlotinib (E) and bortezomib (B) have shown
single-agent activity in patients with non-small cell lung cancer.
We studied the combination of these two novel biologic agents in
vitro using a panel of non-small cell lung cancer cell lines.
Methods: The growth inhibitory effect of E and B were deter-
mined by MTT assay on seven non-small cell lung cancer cell
lines. The data obtained from the growth inhibition assay in
response to the combination of E and B were subject to isobo-
logram analysis. The effects of each individual drug as well as
combination in different sequences on cell cycle and apoptosis
were determined by flow cytometry.
Results: Two of seven cell lines are sensitive to E. However, B has
narrower range of cytotoxicity. The combination is neither syner-
gistic nor additive in two of four cell lines tested. In H358 bron-
choalveolar cell lines, the combination is more active than either
agent alone. E causes G1 cell cycle arrest and B causes G2/M cell
cycle arrest. In sequential studies, 24-hour previous exposure to E
causes G1 arrest and abrogates the cytotoxic effect of B. This is
observed in both E-sensitive as well as E-resistant cells and is
accompanied by an increase in cell survival and a decrease in
apoptosis.
Conclusions: The combination of E and B is neither additive nor
synergistic in two of four cell lines tested. In H358 bronchoalveolar
cell, the combination is more active than either agent alone. The
schedule-dependent antagonistic effect of E pre-exposure was ob-
served. E pre-exposure causes G1 cell cycle arrest and abrogates the
activity of B. Further in vivo studies of this combination are
warranted.
(J Thorac Oncol. 2007;2: 715–721)
Non-small cell lung cancer (NSCLC) remains the leadingcause of cancer deaths in United States. It is estimated
that there will be 213,380 new cases of lung cancer in United
States and 160,390 deaths in 2004.1 NSCLC comprises 80%
of lung cancers.
Chemotherapy remains the mainstay treatment for pa-
tients with metastatic NSCLC. The meta-analysis from 52
randomized trials comparing chemotherapy with best sup-
portive care showed a 10% increase in survival rate and an
improvement of 1.5 months in median survival for cisplatin-
containing regimens.2 Third-generation agents including pac-
litaxel, docetaxel, and gemcitabine were introduced in 1990.
In a large phase III trial, the combination of these agents with
platinum agents resulted in response rates between 20% and
40% and 1-year survival rates between 30% and 50%.3
Despite these advances, the median survival of patients with
metastatic NSCLC remains 8 to 11 months, and, importantly,
the efficacy of currently available chemotherapies appears to
have reached a plateau.4
Aberrations in signal transduction and apoptotic path-
ways are the hallmark of cancers. Upregulated proliferative
and survival signaling via epidermal growth factor receptor
(EGFR) pathway is common in many epithelium-derived
tumors including NSCLC.5 EGFR signaling is associated
with increased cell proliferation, increased angiogenesis, and
reduced apoptosis.6 Overexpression of EGFR has been asso-
ciated with poor prognosis in patients with NSCLC.7 Hence,
targeting the EGFR is the most logical and rational step in the
treatment of NSCLC.8
Erlotinib is a small-molecule EGFR-specific tyrosine
kinase inhibitor that has shown clinical activity in patients
with NSCLC. In a multicenter phase II study, single-agent
erlotinib has 14.3% objective response and 28.6% stable
disease among 46 patients with recurrent NSCLC.9 In a large
randomized, placebo-controlled trial, single-agent erlotinib
prolonged survival compare with placebo in previously
treated NSCLC patients.10 Despite these advances, the activ-
ity of erlotinib is confined to a selective group of patients with
NSCLC and two large randomized trials of combination of
erlotinib with standard chemotherapy as first-line treatment
has so far failed to improve the outcome.11,12
Bortezomib is a novel dipeptide boronate proteasome
inhibitor that is approved by U.S. Food and Drug Adminis-
tration for the treatment of refractory multiple myeloma.13,14
Bortezomib induced concentration- and time-dependent
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G2/M cell cycle arrest of NSCLC cells.15 This was accom-
panied by stabilization of critical cell-cycle regulatory mol-
ecules (p53, p21), activation of caspases, and eventual apo-
ptosis.16,17 In vivo activity was also observed in NSCLC
xenografts as well as a human NSCLC heterotransplant
model (unpublished data).
Clinical activity was also observed in patients with refrac-
tory NSCLC in phase I and II trials.18,19 A large randomized
phase II trial compared bortezomib alone with bortezomib in
combination with standard docetaxel as a second-line therapy in
NSCLC patients. Single-agent bortezomib has 8% response rate
with an additional 21% of patients having stable disease. The
median survival in the bortezomib alone arm was 7.4 months,
comparable with most chemotherapy including taxanes used in
the second-line setting.20
In this work, we studied the combination of these two
novel biologic agents in vitro using a panel of NSCLC cell
lines. Our rationale was that these two agents have shown
clinical activity with no overlapping toxicities and act on
different phases of cell cycle progression. Furthermore, the
activation of EGFR axis has also been shown to activate
nuclear factor-B axis.21 We postulate that by inhibiting both
upstream and downstream targets, the combination of erlo-
tinib and bortezomib will be able to elicit more cytotoxicity.
As previously mentioned, the combination of EGFR inhibi-
tors in chemotherapy has so far failed to improved outcome
and it is essential to have a strong preclinical data before




Erlotinib (OSI-774) was supplied by OSI Pharmaceutical
Inc. (Melville, NY) and bortezomib was obtained from Millen-
nium Pharmaceuticals Inc. (Cambridge, MA). Both agents were
dissolved in DMSO (10 mM) as stock solution and diluted to the
desired concentration with phosphate-buffered saline. Monoclo-
nal antibodies were obtained from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA), and other chemicals were obtained from
Sigma-Aldrich Chemical Co. (St. Louis, MO).
Cell Lines
Seven NSCLC cell lines (H322, H358, H661, H460,
H522, H1299, and A549) were obtained from American Type
Culture Collection (Manassas, VA). All cells were grown in
RPMI 1640 supplemented with 10% fetal bovine serum in a
humidified atmosphere of 5% CO2 and 95% air.
Growth Inhibition Assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT)-tetrazolium dye assay was used to
evaluate the growth inhibitory activity of a drug at various
concentrations. An exponentially growing cell suspension
(5 10 4 cell/ml) were seeded into a 96-well plate overnight,
and then each drug solution at various concentrations was
added. After incubation for 72 hours at 37°C, 20 l of 5
mg/ml MTT solution was added and the cells were further
incubated for 2 hours. The MTT0reduced product by survival
cells was assessed by a microplate reader as previously
described.22 Six replicate wells were used for each drug
concentration, and the experiment was carried out indepen-
dently three to four times.
Data are expressed as a percentage of the control
(vehicle-treated cells), and the IC50 was calculated from the
data. The IC50 is determined as the drug concentration needed
for 50% growth reduction on the survival curve.
Combination Data Analysis by the Isobologram
Method
The data obtained from the growth inhibition assay in
response to the combination of erlotinib and bortezomib were
subject to isobologram analysis. The synergy analysis is per-
formed by using Calcusyn software (Biosoft, Ferguson, MO).
The isobologram method relies on the calculation of the
combined concentrations of erlotinib and bortezomib that
cause a given effect, like 30%, 50%, or 70% of growth
inhibition.23 For each combination of drug concentrations
producing in combination the effect X, the combination index
(CI) was calculated. Each experiment generated a set of CI
values for a particular effect level. The CI values obtained
from all experiments within a given cell line were pooled, and
the mean and variance were calculated. A confidence band
was calculated around each mean using a t distribution at the
90% probability level. The CI values for a particular effect
level were plotted on a graph.
Additivity was claimed when the value CI  1 was
inside the confidence band (with the band included in the
0.8–1.2 level), synergism when the CI with its confidence
band was 1 and antagonism when the CI with the confi-
dence band was 1.
Cell Cycle Analysis
Cells were treated with either erlotinib or bortezomib
alone or in combination, given either concomitantly or se-
quentially 24 hours apart. Cells were harvested at 48 hours
from first drug exposure, fixed with 75% ethanol at 20°C
overnight, and then incubated at room temperature for 3
hours with 5 g/ml propidium iodide and 5 g/ml RNase I
(Roche Molecular Biochemicals, Indianapolis, IN). The num-
ber of cells at different cell cycles and apoptosis (sub-G0/G1)
were measured by flow cytometry (Epics Profile Analyzer;
Coulter Co., Miami, FL).
Western Blot Analysis
Cells were scraped from the culture, washed twice with
phosphate-buffered saline, and then suspended in 60 to 100l of
Western blot lysis buffer containing 50 mM Tris-HCl (pH
7.5), 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1
mM EGTA, 1 mM NaF, 1 mM phenylmethylsulfonyl fluo-
ride, 1 mM dithiothreitol, 20 g/ml leupeptin, 20 g/ml
aprotinin, 0.1% Triton X-100, and 1% sodium dodecyl sulfate
at 0° to 4°C for 15 minutes. After centrifugation at 1500 g for
10 minutes at 0°C, the supernatants were collected, and the
proteins were separated on 10% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis. After electrophoresis,
protein blots were transferred to a nitrocellulose membrane.
The membrane was blocked with 5% nonfat milk in Tris-
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buffered saline with Tween and incubated overnight with the
corresponding primary antibodies at 4°C. After washing three
times with Tris-buffered saline with Tween, the membrane
was incubated at room temperature for 1 hour with horserad-
ish peroxidase-conjugated secondary antibody diluted with
Tris-buffered saline with Tween (1:1000). The detected pro-
tein signals were visualized by an enhanced chemilumines-
cence reaction system (Amersham, Arlington Heights, IL).
Statistic
All results are the average of three independent exper-
iments. The results are presented as mean SD. The synergy
analysis is performed by using Calcusyn software (Biosoft,
Ferguson, MO).
RESULTS
Sensitivity of NSCLC Cells to Erlotinib
and Bortezomib
The cytotoxicities of erlotinib and bortezomib on seven
NSCLC cell lines are shown in Table 1. Only two of seven
NSCLC cell lines tested have IC50 within achievable serum
plasma concentration and are considered sensitive to erlo-
tinib. The rest have IC50s that are 10 times higher and are
considered resistant. Conversely, the bortezomib had a nar-
rower range of activity with IC50 of 10 to 66 nM. Thus, we
chose two cell lines that are sensitive to erlotinib (H322,
H358) and the two that are resistant (A549, H1299) to further
study the combination of two agents.
Combined Cytotoxic Effect of Erlotinib
and Bortezomib
The combined effect of erlotinib and bortezomib in
human NSCLC cells is shown in Figure 1. In two of four cell
lines tested (H322 and A549), the cytotoxic effect of the
combination of erlotinib and bortezomib is neither synergistic
nor additive. The results are equivocal in H358 and H1299
cell lines. The combination index is close to 1 but cross the
confidence band.
Because of the clinical activity of both agents in bron-
choalveolar cancer patients and the equivocal result from
synergy analysis, we further examined the combination in
H358 bronchioalveolar cells. The time-course analysis of
both viable cell count and apoptosis confirmed that the combi-
nation of erlotinib and bortezomib is more active than either
agent alone (Figure 2). Although the effects of erlotinib and
bortezomib are not additive, the combination results in increased
cytotoxicity and apoptosis at 72 hours in H358 cell line.
Effects of Erlotinib and Bortezomib on Cell
Cycle and Apoptosis
We examined the effect of both agents on cell cycle and
apoptosis. Erlotinib caused the cell cycle arrest at G1, most
prominent in sensitive cell. This G1 cell cycle arrest is
accompanied by an increase in apoptosis in sensitive (H322,
H358) but not in resistant (H1299, A549) cells (data not
shown). To determine whether EGFR and expression and
phosphorylation could affect erlotinib-induced cell cycle pro-
gression, we compared the effect of erlotinib on EGFR
expression and activation in both sensitive and resistant cell
lines. We found that there were no differences in baseline
EGFR expression in sensitive and resistant cells. Erlotinib
inhibits the EGF-induced EGFR phosphorylation in both
sensitive and resistant cells (data not shown).
As we previously reported, bortezomib induced cell
cycle arrest at G2/M and the cell cycle arrest was accompa-
nied by a time-dependent increase in apoptosis (data not
shown). The effect of bortezomib induced G2/M arrest, and
apoptosis was more prominent in cell lines with wild-type
p53 (A549) or null p53 (H358, H1299) compared with H322
cell lines with mutant p53 as previously reported.15
Schedule-Dependent Interaction between
Erlotinib and Bortezomib
We then examined the effect of the combination of the
two drugs given sequentially 24 hours apart. Log phase
growing cells were exposed to erlotinib and bortezomib alone
or in combination given either concomitantly or sequentially
given 24 hours apart, and the cell cycle analysis was per-
formed at 48 hours from first drug exposure as mentioned
above. The sequential therapy with bortezomib followed by
erlotinib had similar cell cycle effects as either bortezomib
alone or concomitant exposure. However, the pre-exposure to
erlotinib for 24 hours causes G1 cell cycle arrest and abro-
gates the G2/M effect of bortezomib (Figure 3). This antag-
TABLE 1. In Vitro Growth-Inhibitory Effect of Erlotinib and Bortezomib in Human NSCLC Cell
Lines





H322 Adenocarcinoma 1.04  0.68 48  3
H358 Bronchoalveolar 1.46  0.16 33  11
H661 Large cell 14.10  3.38 21  11
H460 Large cell 11.2  1.8 20  10
H522 Adenocarcinoma 20 66  20
H1299 NSCLC (not specified) 20 33  10
A549 Adenocarcinoma 20 10  10
IC50 is the drug concentration needed for 50% growth reduction on the survival curve. Each value is the mean  SD of three or four
independent experiments. NSCLC, non-small cell lung cancer.
Journal of Thoracic Oncology • Volume 2, Number 8, August 2007 Bortezomib and Erlotinib Interaction
Copyright © 2007 by the International Association for the Study of Lung Cancer 717
onistic effect of erlotinib pre-exposure was seen in both
sensitive cell lines (H322 and H358) and to a lesser extent
in resistant cells (A549 and H1299) and was proportional
to the degree of G1 arrest induced by erlotinib (data not
shown). This cell cycle antagonistic effect is least promi-
nent in H1299 cells, which are most resistant to erlotinib-
induced G1 arrest.
We further examined the consequence of this cell cycle
effect of bortezomib-induced cytotoxicity and apoptosis. As
shown in Figure 4, the erlotinib pre-exposure resulted in an
increase in cell survival and a decrease in apoptosis compared
with bortezomib alone. Again this effect was seen in both
erlotinib-sensitive H358 as well as resistant A549 cells. No
enhanced activity was observed with either concomitant ex-
posure or the reverse sequence with bortezomib followed by
erlotinib compared with bortezomib alone (Figure 4).
Erlotinib Pre-exposure Prevents
Bortezomib-Induced Caspase 3 Activation
Our previous work demonstrated that bortezomib in-
duced generation of reactive oxygen species, and this is
essential for bortezomib induced G2/M arrest and apopto-
FIGURE 1. Combined cytotoxic effect of erlotinib and bortezomib in human non-small cell lung cancer cell lines. The cells
were exposed for 72 hours to a range of combined concentrations of erlotinib and bortezomib. The combination index (CI)
was plotted against fractional effect (Calcusyn software). See Materials and Methods section for details.
FIGURE 2. Combined effect of erlotinib and
bortezomib in the H358 bronchoalveolar cell
line. Log phase growing cell were exposed
to defined concentrations of erlotinib, bort-
ezomib, or their combination. Cell survival
was measured by colony count and expressed
as fraction compared with baseline over a
time course (A). The percentage of apoptosis
measured by flow cytometry was plotted
over a time course (B). All values are mean
SD of three independent experiments.
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sis.16 This reactive oxygen species generation is accompanied
by change in mitochondrial potential with release of cyto-
chrome c into cytosol and eventual activation of effector
caspases including caspase 3. We examined the effect of
different schedules of bortezomib and erlotinib on caspase 3
activation and poly(adenosine diphosphate ribose) polymer-
ase (PARP) cleavage. Erlotinib pre-exposure for 24 h inhibits
bortezomib-induced caspase 3 activation and PARP cleavage.
This was observed in both A549 and H358 cells (Figure 5).
DISCUSSION
This is the first systemic in vitro study of the combi-
nation of bortezomib and erlotinib in NSCLC cell lines. Both
erlotinib and bortezomib have been shown to have clinical
activity in patients with NSCLC, and these agents have
nonoverlapping toxicity. We observed that the cytotoxicity of
erlotinib is selective in our panel of NSCLC cells, whereas
bortezomib has a narrower range of cytotoxicity. The com-
bination of erlotinib and bortezomib is neither additive nor
synergistic in two of four cell lines tested. In H358 bron-
chioalveolar cells, the combination of erlotinib and bort-
ezomib results in increased cytotoxicity and apoptosis than
either agent alone. However, this needs to be confirmed in a
broader panel of bronchoalveolar cell lines and further in vivo
studies are warranted.
We confirmed our previous report that bortezomib
induced G2/M cell cycle arrest in NSCLC cells. This G2/M
arrest is accompanied by a time-dependent increase in apo-
ptosis. Erlotinib, conversely, caused G1 cell cycle arrest. In
erlotinib-sensitive cells, this G1 arrest is accompanied by
increased apoptosis.
The schedule-dependent antagonistic effect erlotinib
pre-exposure observed in our study is very interesting. Erlo-
tinib pre-exposure caused G1 cell cycle arrest and abrogated
the activity of bortezomib. The caspase 3 activation by bort-
ezomib is inhibited by erlotinib pre-exposure. Yang et al.24
reported that c-Jun N-terminal kinase phosphorylation is essen-
tial for bortezomib-induced mitochondrial cytochrome c release
and apoptosis. Further studies are needed to examine the effect
of erlotinib pre-exposure on bortezomib-induced c-Jun N-termi-
nal kinase activation.
Our results underline the importance of treatment
schedules in combinations of active antineoplastic agents.
We are disappointed not to see any increase in activity of
FIGURE 3. Schedule-dependent interaction between bortezomib (B) and erlotinib (E) in H358 human bronchoalveolar cells.
Cells were treated with either bortezomib (B) or erlotinib (C) alone or in combination either concomitantly (D) or sequentially
24 hours apart (E, F). Cell cycle analysis was performed as mentioned in the Materials and Methods section.
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bortezomib and erlotinib from different schedules. Rather,
we noticed the antagonistic effect of erlotinib pre-exposure
on bortezomib-induced cytotoxicity. Erlotinib does not
seem to have a direct antagonistic effect. Rather the cytokinetic
interaction between two novel agents acting on different parts of
the cell cycle is noteworthy. Similar interaction between erlo-
tinib and other G2/M-blocking chemotherapeutic agents has also
been reported.25
FIGURE 4. Effects of schedule-de-
pendent interaction between bort-
ezomib and erlotinib on cell survival
in H358 (A) and A549 (B) cells. Cells
were treated with either bortezomib
(B) or erlotinib (E) alone or in combi-
nation either concomitantly (BE) or
sequentially 24 hours apart (B¡E;
E¡B). Cell survival analysis (A, B) and
apoptosis (C, D) was performed as
mentioned in the Materials and
Methods section. The results are aver-
age of three independent experi-
ments (mean  SD) and expressed as
the percentage of survival compared
with control (100%).
FIGURE 5. Erlotinib pre-exposure prevents bort-
ezomib-induced caspase 3 activation and poly(a-
denosine diphosphate ribose) polymerase (PARP)
cleavage in H358 BAC cells. Cells were treated
with either control (C), bortezomib (B), or erlo-
tinib (E) alone or in combination either concomi-
tantly (BE) or sequentially 24 hours apart (B¡E,
E¡B) Caspase 3 activation and PARP cleavage
were determined by Western blot analysis as men-
tioned in the Materials and Methods section.
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The mechanism by which G1 arrest induced by erlo-
tinib protects cancer cells from the cytotoxic effect of DNA-
damaging agents including bortezomib needs to be elucidated
in further studies. Knudsen et al.26 has previously reported
that the retinoblastoma tumor suppressor protein (RB) may
play a protective role in response to genotoxic stress by
inhibiting cell cycle progression in G1 phase. The phosphor-
ylation of the RB gene neutralizes its antiproliferative func-
tion and is essential for G1 to S transition.27,28 The effect of
erlotinib on RB phosphorylation and its relationship to this
schedule-dependent antagonistic effect of erlotinib needs to
be studied.
Our study has several limitations. Our synergy analysis
was based on in vitro cytotoxicity. Nawrocki et al.29 reported
a study of the combination of docetaxel and bortezomib.
Although no in vitro synergism was observed, the combina-
tion was synergistic in vivo and they explained the paradox
by the combined effect of two drugs on angiogenesis. Our
results, especially the combined effect on H358 bronchoal-
veolar cells, are very interesting and warrant further in vivo
studies.
In summary, the results of the present study demon-
strate that the combination of erlotinib and bortezomib is
more active than either agent alone in H358 bronchoalveolar
cells, but the combination is neither additive nor synergistic
in the NSCLC cell lines studied. The choice of schedule may
be very important in combining erlotinib with bortezomib,
and further in vivo studies are required to further evaluate this
combination.
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